This study builds on decades of work showing that the protein IL-24 attacks cancer broadly, and is the first to deliver the protein using T cells. This approach is in contrast to CAR-T cells, which are built to recognize proteins on the surface of cancer cells and haven’t been successful against solid tumors. Mice with prostate cancer experienced shrinkage of the original tumor as well as distant metastases following treatment with IL-24 T cells.
An innovative new technique that encourages cancer cells in the kidneys to self-destruct could revolutionize the treatment of the disease.
Immune checkpoint inhibitors boost a patient’s immune response against cancer cells, but they can cause potentially life-threatening side effects in some individuals. New research may help clinicians determine which patients are most at risk.
Researchers have discovered that by changing two components of the media used to culture the cells, they can make liver cancer cells behave more like normal liver cells. Rather than using standard serum containing glucose, they used serum from which the glucose had been removed using dialysis and added galactose to the media. This changes the metabolism of the cells making them behave more like normal liver cells.
Hydrogels are often used as drug delivery systems, but to be effective carriers for anti-cancer drugs, they need to be responsive to varied stimuli in the tumor microenvironment. Now, scientists have developed novel hydrogels to effectively deliver drugs to tumor sites in response to temperature and pH changes in the tumor microenvironment. These multi-stimuli-responsive hydrogels can eliminate remnant cancer cells following tumor excision through controlled drug release, offering hope for effective cancer treatment.
Preclinical research shows that the combination of two existing drugs can exploit the metabolic’hunger’ of a particularly aggressive type of neuroblastoma to kill cancer cells without inflicting too much collateral damage to healthy tissue.
One specific protein may be a master regulator for changing how cancer cells consume nutrients from their environments, preventing cell death and increasing the likelihood the cancer could spread, a study has shown.
Viruses churn out genetic material in parts of the cell where it’s not supposed to be. Cancer cells do too. A new study shows that a tumor-suppressor enzyme called DAPK3 is an essential component of a multi-protein system that senses misplaced genetic material in tumor cells, and slows tumor growth by activating the fierce-sounding STING pathway.
Most people relate cholesterol to heart health, but it is also a critical component in the growth and spread of brain cancer. Researchers recently discovered how cholesterol becomes dysregulated in brain cancer cells and showed that the gene responsible for it could be a target for future drugs.
Image analysis utilizing neural networks can help identify details in tissue samples which are difficult to discern by the human eye. A study demonstrated that the technique makes it possible to accurately determine genetic mutations in the cancer cells of patients suffering from myelodysplastic syndrome, a malignant blood disorder.
Researchers describe how pancreatic cancer cells use an alternative method to find necessary nutrients, defying current therapies, to help them grow and spread.
Cancer cells can dodge chemotherapy by entering a state that bears similarity to certain kinds of senescence, a type of ‘active hibernation’ that enables them to weather the stress induced by aggressive treatments aimed at destroying them, according to a new study. These findings have implications for developing new drug combinations that could block senescence and make chemotherapy more effective.
Scientists identified a new function of ADAR1, a protein responsible for RNA editing, discovering that the ADAR1p110 isoform regulates genome stability at chromosome ends and is required for continued proliferation of cancer cells.
A new substance could improve the treatment of persistent cancers. Researchers have developed a new inhibitor that makes drug-resistant tumor cells respond again to chemotherapy. The new substance blocks a protein in the cancer cells that normally transports the cancer drugs back out of the cells.
It is called the “survival protein” because it plays a central role in the growth of cancer cells: survivin influences two important processes in the body’s cells at the same time – cell death and cell division. Chemists and biologists at the University of Duisburg-Essen (UDE) have now succeeded in developing a precise molecule that can bind the protein’s surface at a defined site and switch it off. “Nature Communications” covers the topic.
Researchers reconstructed the evolutionary history of cancer cells in two patients, tracing the timeline of the mutation that causes the disease to a cell of origin. In a 63-year-old patient, it occurred at around age 19; in a 34-year-old patient, at around age 9.
Cancer stem cells that elude conventional treatments like chemotherapy drive long-term cancer growth and relapse. These cells are difficult to isolate and study because of their low abundance and similarity to other stem cells. Researchers have created a new method that can distinguish cancer stem cells, mature cancer cells and otherwise healthy stem cells based on their genetics and gene expression. The findings open new avenues for cancer research personalised medicine.
When the slime mold Dictyostelium discoideum runs out of food, sulfur limitation drives its development from a unicellular to a multicellular organism. Researchers now present the nutrient signaling pathways in this early eukaryote in great detail. Their results show how metabolism may have played a crucial role in the origins of multicellularity. Moreover, the findings also have therapeutic implications for more complex organisms such as humans. Targeting sulfur metabolism in cancer cells may enhance anti-tumor immunity.
Researchers have developed a novel proton therapy technique to more specifically target cancer cells that resist other forms of treatment. The technique is called LEAP, an acronym for ‘biologically enhanced particle therapy.’
Vascular and interventional radiologists report the development of a new ionic liquid formulation that killed cancer cells and allowed uniform distribution of a chemotherapy drug into liver tumors and other solid tumors in the lab. This discovery could solve a problem that has long plagued drug delivery to tumors.
Research groups have discovered a new molecular mechanism that promotes cell migration. The discovery sheds light on the mechanisms that drive uncontrolled movement of cancer cells, and also revises the ‘text book view’ of cell migration.
A world-first discovery could become a game-changer for patients at risk of rapid health deterioration, such as heart complications, stroke, sepsis and cancer. Researchers developed an antibody as a biosensor, to continuously monitor rapid changes in the concentration of EGFR, a protein present on cancer cells and in body fluids.